Investigating nanomedicines to make treatment safer for children with cancer
Looking at how nanoparticles could improve drug delivery and reduce toxicity for young cancer patients.
Protecting young hearts from chemotherapy-related heart problems
Investigating whether giving a medicine before doxorubicin cancer treatment could prevent heart damage.
International clinical trial to test the use of dye during children’s cancer surgery
Testing whether a dye called Indocyanine Green (ICG) can help surgeons identify tumours and lymph nodes during surgery.
Exploring ‘Junk DNA’ to find undiscovered causes of cancer
Using a new way to measure genetic variation in key sections of noncoding DNA.
Investigating immune cells in sarcoma tumours
Finding why immunotherapy doesn't work for some children with sarcoma tumours.
Can radiotherapy near the spleen lead to severe infections later in life?
Looking into whether survivors of childhood cancer are at risk of severe infections.
A study to assess the usefulness of using a dye in combination with keyhole surgery in children with cancer
An open label, single centre, single arm, prospective feasibility study evaluating the effectiveness of near-infrared fluorescence(NIRF)using indo-cyanine green(ICG)in intra-abdominal or intra-thoracic minimally invasive surgery(MIS)in paediatric oncology.
New markers to select children with cancer for trials with PARP inhibitors
Novel biomarkers for PARP inhibitor trials for children with cancer
Phase II clinical trial: Testing a new therapy to treat children with relapsed/ refractory cancers and immune system over-activation conditions
GOTHAM - A phase II trial to assess the activity of Gemtuzumab Ozogamicin Therapy in HAemophagocytic lymphohistiocytosis (HLH)/Macrophage activation syndrome (MAS) or relapsed/refractory cancers